Lung v2

The FusionPlex Lung v2 panel is a targeted next-generation sequencing (NGS) research product that expands on our well-adopted FusionPlex Lung panel to further drive discovery. The updated design covers newly published fusion breakpoints and isoforms of interest in key gene targets (including the NTRKs) and aligns with existing guidelines for non-small cell lung cancer research, including NCCN and ESMO (ESCAT). All gene content from the Lung v1 panel is covered in v2, including EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations. The panel is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.

Thank You

Comprehensive Fusion Detection

AMP chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.

Splice Variants

Detect cancer-associated isoforms and alternative splicing events.

Low Input

Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.

Simple, Lyophilized Workflow

Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turn-around time.

Properties

Specifications

Gene Targets

17 Input Nucleic Acid Required*

≤10ng

Unique Molecular On-Target %

>96%

Sample Types

Fresh frozen and FFPE

Hands-On Time

3.5 hour

Total Time

1.5 days

Platform

Illumina® and Ion Torrent™

*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200ng is recommended.